Novo Nordisk is continuing its push into genetic medicines, agreeing to pay NanoVation Therapeutics up to $600 million to ...
The agreement with NanoVation marks the second big recent deal that a B.C. biotech startup has struck with the Danish ...
Novo Nordisk announced Phase 2a trial results for monlunabant. The trial demonstrated a weight reduction of 7.1 kg with a 10 ...
ME Therapeutics to begin testing of first mRNA formulations from NanoVation Therapeutics collaboration: Vancouver, British Columbia Friday, September 20, 2024, 14:00 Hrs [IST] ME ...
Canada’s NanoVation Therapeutics has partnered with Novo Nordisk to advance genetic medicines for cardiometabolic and rare ...
Canada-based NanoVation Therapeutics announced a multi-year partnership with Novo Nordisk A/S (NYSE:NVO) to advance the ...
NanoVation Therapeutics, a Vancouver company co-founded by biotech magnate Pieter Cullis, has struck a partnership with ...
NanoVation will receive $600m in upfront cash and potential milestone payments, as well as tiered royalties on future product ...
The firms will collaborate on two lead programs and up to five future targets in other diseases, with NanoVation eligible for up to $600 million in payments from Novo Nordisk.
ME Therapeutics Holdings Inc. Vancouver, British Columbia–(Newsfile Corp. – September 18, 2024) – ME Therapeutics Holdings ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback